Mölndal, Sweden

Hans Carlsson


 

Average Co-Inventor Count = 4.4

ph-index = 1

Forward Citations = 118(Granted Patents)


Location History:

  • Mölndal, SE (2005)
  • Molndal, SE (2019)

Company Filing History:


Years Active: 2005-2019

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Inventor Hans Carlsson in the Pharmaceutical Field

Introduction

Hans Carlsson is an accomplished inventor based in Molndal, Sweden, recognized for his significant contributions to the field of pharmaceuticals. With a focus on enhancing drug delivery systems, Carlsson has developed innovative formulations aimed at improving patient outcomes. His work involves the formulation of millicapsules that optimize the use of polyunsaturated free fatty acids.

Latest Patents

Hans Carlsson holds a patent for "Millicapsule formulations comprising polyunsaturated free fatty acids." This patent details capsular dosage forms containing polyunsaturated fatty acid (PUFA) compositions. The invention includes unit dosage forms comprising a plurality of millicapsules filled with PUFA compositions, along with methods for their use and manufacture. Notably, certain embodiments highlight a PUFA composition known as Epanova®.

Career Highlights

As a key member of Omthera Pharmaceuticals Inc., Hans Carlsson has made significant strides in the pharmaceutical sector, focusing on innovative approaches to drug delivery and efficacy. His extensive research and development efforts have established him as a leading figure in developing formulations that address therapeutic needs effectively.

Collaborations

Throughout his career, Hans Carlsson has collaborated with numerous experts, including notable coworkers Hironori Kubota and Etienne Thierry Charles Rogeau. These collaborations have fueled advancements in their collective work, enhancing the scope and impact of their research in pharmaceuticals.

Conclusion

Hans Carlsson’s dedication to innovation in pharmaceutical formulations has led to significant advancements, particularly in the area of PUFA dosage forms. As he continues to work with Omthera Pharmaceuticals Inc. and collaborate with fellow researchers, his contributions are poised to have a lasting impact on the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…